Title
Category
Credits
Event date
Cost
  • Alzheimer Disease
  • Dementia
  • Integrated Care
  • Neuroimaging
  • Patient/Physician Communication
  • Primary Care
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Prompt treatment of early-stage Alzheimer disease (AD) can curb symptom progression. Tests for biomarkers, new symptomatic treatments and disease-modifying agents, and the addition of the preclinical stage to AD diagnostic criteria can aid in earlier disease recognition and building treatment plans.
  • Muscular Dystrophy
  • Psychopharmacology
  • Patient/Physician Communication
  • Obsessive-Compulsive and Related Disorders
  • Violence/Aggression
  • Sleep
  • Side Effects
  • Delivery of Care
  • Cognition
  • Child and Adolescent Psychiatry
  • Depression
  • Attention-Deficit/Hyperactivity Disorder
  • Diagnostic Tools
  • Weight
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
This video reviews treatment guidelines for patients with DMD and emphasizes the importance of clinicians intervening early on behalf of individuals who develop behavioral-psychosocial comorbidities.
  • Renal Disease
  • Primary Care
  • Patient/Physician Communication
  • Side Effects
  • Cardiology
  • Metabolic Disorders
  • Diagnostic Tools
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
How to screen UACR and eGFR levels, implement selective non-steroidal MRA therapies, and mitigate the risk of hyperkalemia to prevent CKD disease progression
  • Myasthenia Gravis
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Symptoms and disease pathophysiology of myasthenia gravis (MG) vary considerably with each patient, and their individual preferences and priorities add to the need for individualized treatment of this autoimmune disease. Research in MG has grown substantially in recent years. New treatments have the potential of being both effective and well tolerated, addressing the trade-off of choosing either efficacy or tolerability when selecting treatments. Promising investigational treatments that may become available in the future may allow more patients than ever before to achieve an asymptomatic state, with the ultimate goal being to turn off abnormal antibody production.
  • Child and Adolescent Psychiatry
  • COVID-19
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Long COVID symptoms are both physical and mental in nature among children and adolescents and have the potential to affect long-term functioning and increase the overall burden on health care delivery.
  • Alzheimer Disease
  • Dementia
  • Diagnostic Tools
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Great strides in research on Alzheimer disease diagnostic biomarkers and treatment targets have taken place over the past 2 decades. Listen as Dr Goldfarb highlights exciting developments.
  • Dementia
  • Geriatric Psychiatry
  • Psychotic Disorders
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Dementia-related psychosis (DRP) occurs in all forms of dementia and at all stages. What tactics should be used when talking with patients and their care partners about DRP? How is it best treated?
  • Alzheimer Disease
  • Cognition
  • Dementia
  • Diagnostic Tools
  • Patient/Physician Communication
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
In this webcast about early-stage Alzheimer disease, Drs Burke and Apostolova highlight important conversations to have with patients and their care partners on topics such as diet, exercise, driving, and plans for the later stage of illness.
  • Alzheimer Disease
  • Neurology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
How do investigational drugs for Alzheimer disease differ from those currently prescribed to patients? Dr Burke shares her insights.
  • Alzheimer Disease
  • Dementia
  • Diagnostic Tools
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Experts offer an overview of best practices for managing early-stage Alzheimer disease as well as a look at the future.

Pages